WO2015027730A1 - 显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法 - Google Patents
显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法 Download PDFInfo
- Publication number
- WO2015027730A1 WO2015027730A1 PCT/CN2014/079771 CN2014079771W WO2015027730A1 WO 2015027730 A1 WO2015027730 A1 WO 2015027730A1 CN 2014079771 W CN2014079771 W CN 2014079771W WO 2015027730 A1 WO2015027730 A1 WO 2015027730A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- beef
- chinese medicine
- traditional chinese
- powder
- jisheng
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 102000015779 HDL Lipoproteins Human genes 0.000 title claims abstract description 48
- 108010010234 HDL Lipoproteins Proteins 0.000 title claims abstract description 48
- 239000002131 composite material Substances 0.000 title claims abstract 7
- 238000002360 preparation method Methods 0.000 title claims description 13
- 230000001965 increasing effect Effects 0.000 title abstract description 7
- 235000015278 beef Nutrition 0.000 claims abstract description 36
- 210000002435 tendon Anatomy 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 6
- 108090000790 Enzymes Proteins 0.000 claims abstract description 4
- 102000004190 Enzymes Human genes 0.000 claims abstract description 4
- 230000007062 hydrolysis Effects 0.000 claims abstract description 4
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract 2
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract 2
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract 2
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract 2
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract 2
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract 2
- 241000283074 Equus asinus Species 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 241001247821 Ziziphus Species 0.000 claims description 12
- 235000013372 meat Nutrition 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 9
- 235000008434 ginseng Nutrition 0.000 claims description 9
- 235000021120 animal protein Nutrition 0.000 claims description 4
- 239000003531 protein hydrolysate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 241001633583 Adenophora Species 0.000 claims 3
- 241001092040 Crataegus Species 0.000 claims 3
- 241000244365 Ligusticum sinense Species 0.000 claims 3
- 235000014493 Crataegus Nutrition 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 claims 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 108090000526 Papain Proteins 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 238000000703 high-speed centrifugation Methods 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000002893 slag Substances 0.000 claims 1
- 229940126589 solid medicine Drugs 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 abstract description 6
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 244000146486 Glehnia littoralis Species 0.000 abstract 1
- 235000004036 Glehnia littoralis Nutrition 0.000 abstract 1
- 235000002598 Inula helenium Nutrition 0.000 abstract 1
- 244000116484 Inula helenium Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 10
- 241000208340 Araliaceae Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 239000004576 sand Substances 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 241001076939 Artines Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 240000003167 Crataegus douglasii Species 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 235000009941 northern hawthorn Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000004141 reverse cholesterol transport Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to the field of prevention and treatment of heart and cerebrovascular diseases caused by atherosclerotic arch, with sputum and a significantly elevated serum High-density lipoprotein (HD concentration of traditional Chinese medicine compound prescription).
- High density lipoprotein is mainly composed of liver and small intestine, and the smallest serum lipoprotein.
- Dr. Miller of the United States first discovered the anti-atherosclerosis factor HDL, which revealed that coronary heart disease is not always caused by hyperlipidemia.
- the decrease of HDL level may also be an important or even key for coronary heart disease.
- the cause of sexual onset is mainly composed of liver and small intestine, and the smallest serum lipoprotein.
- HDL high-density lipoprotein
- HDL has a clear anti-atherosclerotic effect, which can "absorb” cholesterol from the atherosclerotic blood vessel wall and transport it to the liver for elimination.
- Arterial angiography also confirmed a significant negative correlation between HDL content and arterial lumen stenosis, so HDL has the reputation of "vascular scavenger”.
- the international medical community clearly understands J ⁇ "Who can significantly increase HDL, who solves the problem of coronary heart disease and even cardio-cerebral vascular disease, who can theoretically extend human silk for decades.
- the object of the present invention is to provide a traditional Chinese medicine compound composition which significantly raises serum HDL, and to make up for the deficiencies of the prior art, so as to change the current state of clinical use of a traditional Chinese medicine which does not have an ideal serum HDL.
- the traditional Chinese medicine compounding group of the invention is composed of the following two aspects: “Tune the middle piece” and “Jisheng San”.
- the middle slice of the present invention is composed of the following drugs: Beishan, Muxiang, Beisha, and Chuanxiong, wherein the weight percentage of each component is: Beishan ⁇ 30 Q / M0%, woody 10% - 30%, Northern sand ginseng 103 ⁇ 4 ⁇ _30%, Chuanxiong 10% - 30%.
- the percentage of each component of the middle-adjusting tablet of the present invention may also be: Beishan ⁇ 353 ⁇ 4 ⁇ " 45%, wood incense 15% - 25%, Northern sand ginseng 15% - 25%, j 11 ⁇ 15% - 25%
- each component of the middle plate is: 40% of the northern hawthorn, 20% of the woody, 18% of the northern sand ginseng, and 22% of the Chuanxiong.
- the main component of the middle tune is woody, medicinal, bitter, warm, Adjust the lead stagnation, spleen and digestion, the role of iM.
- the drug is the drug.
- Beishan Mountain Another important ingredient in the middle of the film is Beishan Mountain, which is medicinal acid, sweet, and lukewarm. It has the function of digestion and digestion, promoting blood circulation and removing blood stasis. Studies have shown that B. hawthorn can reduce blood lipids, improve blood circulation, prevent surface ion transmission, help stabilize myocardial, antihypertensive, and anti-atherosclerosis. In the middle of the film is a drug.
- the four-flavor medicine in the middle of the film of the invention has the functions of nourishing the qi, invigorating the spleen and appetizing, correcting the deficiency of the spleen and stomach, restoring the normal physiological function of the spleen and stomach, and also having the functions of nourishing yin, promoting blood circulation and removing blood stasis.
- the main focus of this disease is to start from the conditioning of the spleen and stomach function, the amino acid that is essential for the synthesis of LDL, the obstacles in the process of digestion, absorption and transformation of the human body as a therapeutic target, first restore the human body environment to synthesize the ideal HDL 7JC flat
- the physiological basis has created a cake for the application of Jishengsan and its full effect, which is the key to significantly increase serum HDL concentration.
- the preparation method of the middle film is a traditional Chinese medicine pharmaceutical process. 7 fried, m, made into tablets; can also be made into 1", pills, capsules.
- the Jishengsan of the present invention is composed of the following drugs: beef, beef tendon, pig skin, jujube meat, wherein the weight percentage of each component is: beef 403 ⁇ 4 ⁇ "60%, beef tendon 15°/( ⁇ -35%, pig skin 15 ° / ( ⁇ - 35%, jujube meat 0. 5% - 2. 5%
- the percentage of the components of the Jisheng San of the present invention may also be: beef 45 ° / ⁇ 5%, Beef tendon 20% - 30% pig skin 20% - 30%, jujube meat I 0 / 2%
- each component of Jishengsan is: beef 50%, beef tendon 24%, pig skin 25%, jujube meat
- Jishengsan the main ingredient in Jishengsan is beef, which is sweet, warm and non-toxic, and has the effect of protecting the qi and stomach. Rich in beef protein, it is the main source of amino acids. In the Jisheng San is a drug.
- Jishengsan Another important ingredient in Jishengsan is pig skin, which is sweet and cool, rich in collagen, followed by elastin, which nourishes yin and raises bloody skin. @@ ⁇ , lowers blood viscosity, resists blood clots, improves microcirculation The role.
- Pig skin can be replaced by cowhide, suede, or other large mammalian swordsmen.
- Jisheng San is a drug.
- Beef tendons can be replaced by beef tendons, or other large mammals with tendons (legs) or tendons.
- Jisheng San is an adjuvant.
- the jujube meat in Jishengsan is sweet, flat, non-toxic, beneficial to the spleen and stomach, and it is used as a flavoring agent.
- Jisheng San for the medicine.
- the beef, beef tendon and pig skin in Jisheng San are all flesh and blood, have a strong qi and nourishing effect, improve the body's copper dog condition, anti-aging, and significantly enhance human immunity. effect.
- Jisheng is in the treatment of the standard, and the active ingredient of the drug is animal protein hydrolysate, which is composed of a variety of amino acids as the main component.
- the pharmacological action of the nutrient is the body's synthesis of HDL. It has a variety of amino acids that are highly efficient and sufficient to provide the ideal HDL levels for human synthesis. It is a substance that raises the serum HDL concentration.
- the preparation method of Jishengsan is to use the earning hydrolysis process. Add the appropriate amount of water to the container and add the Artin Hydrolase. The reaction is carried out to prepare animal protein hydrolysate.
- the combination of the middle-adjusting tablets and the Jishengsan of the present invention can cooperate with each other, complement each other, and synergistically play a role of significantly increasing the serum HDL concentration, and is suitable for the prevention of heart and cerebrovascular diseases caused by atherosclerosis. Treatment; can also be used for anti-aging.
- the spleen and stomach are the hubs of the body's qi and qi.
- the spleen is promoted by the spleen (liver, kidney, trifocal, small intestine, large intestine), and the stomach is descended (pulmonary, heart, pericardium, gallbladder).
- the bladder can be lowered; the human body can reach the realm of no stagnation of the meridians and qi and blood, and the nutrients in the body can be fully digested, absorbed, transported, metabolized, secreted and excreted. This is the physiological basis for the human body to synthesize the ideal HDL 7 flat.
- the medium-adjusting tablet of the invention focuses on conditioning the spleen and stomach, recovering the cardinal of normal lifting, thereby making the body's internal gas rise and fall normally and orderly; improving the internal environment of the human body to achieve an ideal state of balance, neutrality and harmony.
- the nutrients such as amino acids necessary for listening to the ideal LDL level of 1J human body can be fully digested, absorbed and efficiently reported. Therefore, the medium is adjusted to increase the serum HDL concentration of the base drug.
- Nutritional immunology also tells us that human beings have an awesome, sophisticated and complex system. Only the system is healthy and powerful. Cancer can recover quickly like a cold. In addition to hereditary diseases, almost human diseases. Both are related to the immune response. Enhancing human immunity and keeping it functioning properly, most human diseases are expected to be cured. The only way for people to do everything is to provide adequate nutrition to the immune system, restore it and stay healthy and strong, and recover even if it is sick. This is the secret of health and longevity. This theory is consistent with the academic thought of the Yellow Emperor's internal classics, "Positive in the air, evil can not be done.”
- the traditional Chinese medicine compounding group of the invention is composed of two parts: “Tune in the middle” and “Jishengsan”.
- Preparation method The four-flavored medicine of the middle-adjusting tablet is uniformly mixed and rinsed with water, and then 1/10 of the total weight is weighed out for drying and pulverization to prepare a dry powder for use; and then processed according to the traditional Chinese medicine pharmaceutical process; The process: soaking the remaining drugs ⁇ decoction ⁇ filtration ⁇ «
- Preparation method of Jishengsan mmtm, ? rinse; beef, beef tendon, pig skin should be cut into small pieces or strips; then cook them 10 H ⁇ i5 j finely, add water to make a suitable paste; Then it is processed by the Lancui hydrolysis process.
- paste drug add papaya protein hydrolysis at 60 ° C for 12 hours for hydrolysis reaction ⁇ boil 15 off! ⁇ High-speed centrifugal degreasing, desiccation ⁇ filtration ⁇ liquid animal protein hydrolysate ⁇ concentration ⁇ spray drying ⁇ package ⁇ ⁇ Powdered finished product. Cong 10 ⁇ 15 grams.
- the tablets, powders, and pellets obtained from the three examples of the middle sheet can be combined with the powdered products obtained from the three examples of Jishengsan.
- the traditional Chinese medicine compound group _Tiaozhong tablets and Jishengsan can significantly increase the serum HDL concentration, and the effect is superior to the western medicine niacin and statins, and is a traditional Chinese medicine which advocates the potential of great value in nature.
- the Jisheng Powder of the present invention is rich in a variety of amino acids, and is a main substance constituting various immune cells, antibodies, complements and the like of the human body. Only in the case of a wide variety of amino acids and a sufficient number of cattle, the human body can normally synthesize various immune cells, antibodies, complements, etc., wherein the present invention significantly enhances the body's immunity and keeps the immune system healthy and powerful. The vast majority of diseases, including serum HDL 7 levels, are expected to be cured.
- the serum HDL concentration value of the subject at the beginning is the baseline, and the serum HDL concentration value of the subject is the largest in the first to sixth years after administration.
- the increase was 92.6%, and the minimum increase was 43.9%.
- the median serum HDL concentration in 6 years was 65.6% higher than the baseline; no obvious side effects, liver and kidney function were observed. No abnormalities have been observed.
- This experiment confirmed that the present invention can greatly increase serum HDL concentration, and its effect is superior to western medicine niacin and statins.
- the present invention can significantly increase the serum HDL concentration, and has no obvious toxic and side effects, and can be cut for a long time; although the effect is slow (at least 3 months), the effect is stable and long-lasting after the effect; and can be combined with statins.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016537097A JP6273017B2 (ja) | 2013-08-30 | 2014-06-12 | 血清高密度リポタンパク質(hdl)濃度を著しく増加させる漢方薬複合組成物及び製造方法 |
US14/771,505 US9861664B2 (en) | 2013-08-30 | 2014-06-12 | Traditional chinese medicine complex composite for significantly improving high density lipoprotein concentration in serum and preparation method thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310384204.5 | 2013-08-30 | ||
CN201310384204.5A CN103405538B (zh) | 2013-08-30 | 2013-08-30 | 显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015027730A1 true WO2015027730A1 (zh) | 2015-03-05 |
Family
ID=49598612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/079771 WO2015027730A1 (zh) | 2013-08-30 | 2014-06-12 | 显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9861664B2 (zh) |
JP (1) | JP6273017B2 (zh) |
CN (1) | CN103405538B (zh) |
WO (1) | WO2015027730A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103405538B (zh) * | 2013-08-30 | 2014-07-23 | 高庄存 | 显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法 |
CN105079774A (zh) * | 2015-09-18 | 2015-11-25 | 高庄存 | 一种升高hdl的组合物及其应用 |
US11448013B2 (en) | 2018-12-05 | 2022-09-20 | Epiroc Drilling Solutions, Llc | Method and apparatus for percussion drilling |
CN111184221B (zh) * | 2019-10-21 | 2023-06-27 | 青海宏健生物科技集团有限公司 | 一种牦牛蹄筋胶原蛋白口服液及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101069731A (zh) * | 2007-05-11 | 2007-11-14 | 赵震峰 | 治疗高血压的中成药胶丸及制备方法 |
CN102940255A (zh) * | 2012-11-29 | 2013-02-27 | 蒋科富 | 一种牛肉肠 |
CN103405538A (zh) * | 2013-08-30 | 2013-11-27 | 高庄存 | 显著升高血清高密度脂蛋白浓度的中药复合组方和制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1320916C (zh) * | 2005-04-15 | 2007-06-13 | 吴金珠 | 治疗高血脂症的降脂通脉中药 |
US20070059386A1 (en) * | 2005-09-12 | 2007-03-15 | Tsun-Nin Lee | Modular system for novel Chinese herbal formulas |
CN100522197C (zh) * | 2006-06-23 | 2009-08-05 | 陕西香菊药业集团有限公司 | 治疗高脂血症的中药制剂及其制备方法 |
-
2013
- 2013-08-30 CN CN201310384204.5A patent/CN103405538B/zh active Active
-
2014
- 2014-06-12 US US14/771,505 patent/US9861664B2/en not_active Expired - Fee Related
- 2014-06-12 JP JP2016537097A patent/JP6273017B2/ja active Active
- 2014-06-12 WO PCT/CN2014/079771 patent/WO2015027730A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101069731A (zh) * | 2007-05-11 | 2007-11-14 | 赵震峰 | 治疗高血压的中成药胶丸及制备方法 |
CN102940255A (zh) * | 2012-11-29 | 2013-02-27 | 蒋科富 | 一种牛肉肠 |
CN103405538A (zh) * | 2013-08-30 | 2013-11-27 | 高庄存 | 显著升高血清高密度脂蛋白浓度的中药复合组方和制备方法 |
Non-Patent Citations (1)
Title |
---|
HU , YONGHE: "Recent Development for Treatment of Diabetes and Hyperlipemia by Chinese s Medicine", JETCM, vol. 14, 31 July 2005 (2005-07-31) * |
Also Published As
Publication number | Publication date |
---|---|
US9861664B2 (en) | 2018-01-09 |
CN103405538B (zh) | 2014-07-23 |
US20160008406A1 (en) | 2016-01-14 |
JP6273017B2 (ja) | 2018-01-31 |
JP2016529261A (ja) | 2016-09-23 |
CN103405538A (zh) | 2013-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3530277A1 (en) | Chinese medicine healthcare preparations for slimming and weight loss | |
CN105727081A (zh) | 一种用于治疗痛风的保健品组合物 | |
CN105126067A (zh) | 一种降尿酸的组合物及其用途 | |
WO2010054520A1 (zh) | 净化血管的药物组合物及其制备方法 | |
WO2015027730A1 (zh) | 显著升高血清高密度脂蛋白浓度的中药复合组合物和制备方法 | |
CN104432050A (zh) | 一种猴头菇营养羹及其制备方法 | |
CN104473169B (zh) | 一种含鱼胶的保健品及其制备方法 | |
CN106418132A (zh) | 一种山药降血脂粉及其制备方法 | |
CN103893613A (zh) | 一种治疗口腔溃疡的药物及制备方法 | |
CN103494198A (zh) | 解酒汤料的配方及其生产方法 | |
CN113925172A (zh) | 一种适用于儿童的大鲵肽营养组合物 | |
CN105688110A (zh) | 一种阿胶补血养颜口服液及其生产方法 | |
CN104800600A (zh) | 一种治疗高血压的药物 | |
CN104013853B (zh) | 一种健肾补肾的组合物及其制备方法 | |
CN103932001B (zh) | 一种具有减肥、调节血脂的保健食品及其制备方法 | |
CN114632098B (zh) | 一种利用鸡血藤制备黄酮精制物的方法 | |
CN106551312A (zh) | 一种中老年益寿糕 | |
CN105168369A (zh) | 一种螺旋藻强体抗衰老酒及其制备方法 | |
CN105687985A (zh) | 一种补骨脂暖脾止泻口服液及其生产方法 | |
CN102824572B (zh) | 排毒保健的中药及其制备方法 | |
CN105687808A (zh) | 一种白及收敛止血口服液及其生产方法 | |
CN104522573A (zh) | 一种和胃降逆的葛根粉 | |
CN103783479A (zh) | 黑虎掌菌补脑健脑火锅调料及其生产方法 | |
CN103829197A (zh) | 一种党参益气生津火锅料及生产方法 | |
CN104069371A (zh) | 一种辅助治疗月经不调的保健泡腾片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14839226 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14771505 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016537097 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14839226 Country of ref document: EP Kind code of ref document: A1 |